Pacific Biosciences of California, Inc. (PACB) Revenue History
Annual and quarterly revenue from 2008 to present
PACB Revenue Over Time (2008–2025)
PACB Revenue Growth History
10 of 17 years with positive growth- FY2008 revenue growth
- N/A
- FY2009 revenue growth
- -85.0%
- FY2010 revenue growth
- +1140.0%
- FY2011 revenue growth
- +1922.9%
- FY2012 revenue growth
- -23.3%
- FY2013 revenue growth
- +8.5%
- FY2014 revenue growth
- +115.0%
- FY2015 revenue growth
- +53.1%
- FY2016 revenue growth
- -2.2%
- FY2017 revenue growth
- +3.0%
- FY2018 revenue growth
- -15.9%
- FY2019 revenue growth
- +15.6%
- FY2020 revenue growth
- -13.2%
- FY2021 revenue growth
- +65.4%
- FY2022 revenue growth
- -1.7%
- FY2023 revenue growth
- +56.3%
- FY2024 revenue growth
- -23.2%
- FY2025 revenue growth
- +3.9%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $37.2M | +0.1% |
| Q4 2025 | $44.6M | +13.8% |
| Q3 2025 | $38.4M | -3.8% |
| Q2 2025 | $39.8M | +10.4% |
| Q1 2025 | $37.2M | -4.3% |
| Q4 2024 | $39.2M | -32.8% |
| Q3 2024 | $40.0M | -28.2% |
| Q2 2024 | $36.0M | -24.3% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
PACB's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
PACB Revenue Analysis (2008–2025)
Current Revenue & Growth
As of June 22, 2026, Pacific Biosciences of California, Inc. (PACB) generated trailing twelve-month (TTM) revenue of $160.0 million, reflecting modest growth of +0.1% year-over-year. The most recent quarter (Q1 2026) recorded $37.2 million in revenue, down 16.7% sequentially.
Historical Growth Trajectory
PACB's 5-year compound annual growth rate (CAGR) stands at +15.2%, indicating consistent double-digit revenue growth. The 3-year CAGR of +7.6% is below the 5-year average, signalling a growth deceleration in recent years. Pacific Biosciences of California, Inc.'s highest annual revenue of $200.5 million was recorded in 2023.
Revenue by Segment
PACB's revenue is primarily driven by Product (46%), Consumable (28%), and Instrument (18%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including ILMN (+1.2% YoY), BFLY (+20.2% YoY), and CDNA (+19.2% YoY) — PACB has underperformed the peer group in revenue growth. Compare PACB vs ILMN →
PACB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PACBCurrent | $160M | +0.1% | +15.2% | -348.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 BFLY | $98M | +20.2% | +16.1% | -88.5% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 TMO | $44.6B | +5.4% | +6.7% | 18.2% | |
 DHR | $24.6B | +4.0% | +2.0% | 20.9% |
PACB Historical Revenue Data (2008–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $160.0M | +3.9% | $50.7M | 31.7% | $-557,561,000 | -348.5% |
| 2024 | $154.0M | -23.2% | $37.3M | 24.2% | $-474,313,000 | -308.0% |
| 2023 | $200.5M | +56.3% | $52.8M | 26.3% | $-334,467,000 | -166.8% |
| 2022 | $128.3M | -1.7% | $49.0M | 38.2% | $-307,196,000 | -239.4% |
| 2021 | $130.5M | +65.4% | $58.9M | 45.1% | $-210,435,000 | -161.2% |
| 2020 | $78.9M | -13.2% | $32.6M | 41.3% | $-104,385,000 | -132.3% |
| 2019 | $90.9M | +15.6% | $34.6M | 38.0% | $-100,545,000 | -110.6% |
| 2018 | $78.6M | -15.9% | $25.1M | 31.9% | $-100,987,000 | -128.4% |
| 2017 | $93.5M | +3.0% | $34.7M | 37.1% | $-89,784,000 | -96.1% |
| 2016 | $90.7M | -2.2% | $44.2M | 48.7% | $-71,244,000 | -78.5% |
| 2015 | $92.8M | +53.1% | $53.5M | 57.6% | $-29,134,000 | -31.4% |
| 2014 | $60.6M | +115.0% | $23.4M | 38.6% | $-62,854,000 | -103.7% |
| 2013 | $28.2M | +8.5% | $6.4M | 22.8% | $-77,543,000 | -275.2% |
| 2012 | $26.0M | -23.3% | $940K | 3.6% | $-94,338,000 | -363.1% |
| 2011 | $33.9M | +1922.9% | $13.0M | 38.5% | $-109,756,000 | -324.1% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PACB — Frequently Asked Questions
Quick answers to the most common questions about buying PACB stock.
Is PACB's revenue growth accelerating or slowing?
PACB revenue growth is slowing. TTM revenue is $160M, up +0.1% year-over-year — below the 5-year CAGR of +15.2%. The deceleration suggests maturing end-markets or increased competition.
What is PACB's revenue history from 2008 to 2026?
Pacific Biosciences of California, Inc. (PACB) revenue history spans 2008 to 2026. TTM revenue as of 2026 is $160M, growing at +0.1% YoY. The 5-year CAGR is +15.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is PACB's long-term revenue growth rate (CAGR)?
Pacific Biosciences of California, Inc.'s 5-year revenue CAGR of +15.2% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of +0.1% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for PACB.
Why does PACB's quarterly revenue fluctuate?
PACB quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Pacific Biosciences of California, Inc.'s revenue data from 2008 to 2026 shows full historical quarterly detail on this page.
How is PACB's revenue distributed by segment?
PACB reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does PACB's revenue compare to industry peers?
Pacific Biosciences of California, Inc. (PACB) with TTM revenue of $160M and +0.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.